- Home
- RPID vs NTHI Comparison
RPID vs NTHI Comparison
Compare RPID & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RPID | NTHI |
|---|---|---|
| Founded | 2006 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 204.3M | 178.4M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | RPID | NTHI |
|---|---|---|
| Price | $2.40 | $4.29 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $8.00 | ★ $15.00 |
| AVG Volume (30 Days) | ★ 189.8K | 58.1K |
| Earning Date | 05-08-2026 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 2.78 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $33,587,000.00 | N/A |
| Revenue This Year | $19.12 | N/A |
| Revenue Next Year | $18.42 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 19.74 | N/A |
| 52 Week Low | $2.01 | $3.20 |
| 52 Week High | $4.94 | $12.99 |
Technical Indicators
Market Signals| Indicator | RPID | NTHI |
|---|---|---|
| Relative Strength Index (RSI) | 47.98 | 27.13 |
| Support Level | $2.36 | $4.25 |
| Resistance Level | $2.46 | $5.82 |
| Average True Range (ATR) | 0.13 | 0.49 |
| MACD | 0.07 | 0.04 |
| Stochastic Oscillator | 77.53 | 31.52 |
Price Performance
Historical ComparisonAbout RPID Rapid Micro Biosystems Inc.
Rapid Micro Biosystems Inc is an life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company's flagship Growth Direct platform automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in the pharmaceutical manufacturing operations across the globe. It derives revenue from development, manufacturing, marketing and selling Systems and related LIMS connection software, consumables and services.
About NTHI NeOnc Technologies Holdings Inc.
NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration (FDA).